- Home
- TAIT vs APRE Comparison
TAIT vs APRE Comparison
Compare TAIT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAIT
- APRE
- Stock Information
- Founded
- TAIT 1989
- APRE 2006
- Country
- TAIT United States
- APRE United States
- Employees
- TAIT N/A
- APRE N/A
- Industry
- TAIT Electronic Components
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAIT Technology
- APRE Health Care
- Exchange
- TAIT Nasdaq
- APRE Nasdaq
- Market Cap
- TAIT 16.0M
- APRE 15.8M
- IPO Year
- TAIT 1995
- APRE 2019
- Fundamental
- Price
- TAIT $2.60
- APRE $3.85
- Analyst Decision
- TAIT
- APRE Strong Buy
- Analyst Count
- TAIT 0
- APRE 2
- Target Price
- TAIT N/A
- APRE $15.50
- AVG Volume (30 Days)
- TAIT 13.6K
- APRE 33.0K
- Earning Date
- TAIT 11-14-2024
- APRE 11-07-2024
- Dividend Yield
- TAIT 7.69%
- APRE N/A
- EPS Growth
- TAIT N/A
- APRE N/A
- EPS
- TAIT 0.22
- APRE N/A
- Revenue
- TAIT $4,343,000.00
- APRE $1,310,839.00
- Revenue This Year
- TAIT N/A
- APRE $134.21
- Revenue Next Year
- TAIT N/A
- APRE N/A
- P/E Ratio
- TAIT $11.65
- APRE N/A
- Revenue Growth
- TAIT N/A
- APRE 130.31
- 52 Week Low
- TAIT $2.52
- APRE $2.15
- 52 Week High
- TAIT $3.34
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- TAIT 48.86
- APRE 56.63
- Support Level
- TAIT $2.55
- APRE $3.34
- Resistance Level
- TAIT $2.68
- APRE $3.83
- Average True Range (ATR)
- TAIT 0.06
- APRE 0.42
- MACD
- TAIT 0.01
- APRE 0.01
- Stochastic Oscillator
- TAIT 50.00
- APRE 36.04
About TAIT Taitron Components Incorporated
Taitron Components Inc is a supplier of originally designed and manufactured (ODM) products that include value-added engineering and turn-key solutions. It focuses on providing original equipment manufacturers (OEMs) and contracts electronic manufacturers (CEMs) with ODM products for their multi-year turn-key projects and ODM electronic components. The company's product offerings range from discrete semiconductors to small electronic devices. The company also distributes brand-name electronic components with a vast inventory available on hand. Its Taiwan and China locations provide support for inventory sourcing, purchases, and coordinating the manufacture of ODM Projects and ODM Components.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.